Disc Medicine (IRON) Change in Account Payables (2020 - 2026)
Disc Medicine's (IRON) quarterly Change in Account Payables came in at $2.7 million in Q1 2026, up 314.64% year-on-year from $661049.5 in Q1 2025, and up 56.63% on a QoQ basis from $1.8 million in Q4 2025.
Disc Medicine (IRON) Change in Account Payables (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Change in Account Payables data on file, last reported at $2.7 million in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 314.64% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 262.91% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 122.86% from the prior year.
- Change in Account Payables for Q1 2026 stood at $2.7 million, up from $1.8 million in the prior quarter.
- Over the last five years, Change in Account Payables for IRON reached as high as $4.4 million in Q4 2024 and fell as low as -$10.8 million in Q1 2023.
- Historically, Change in Account Payables has averaged -$240294.1 across 5 years, with a median of -$321000.0 in 2025.
- On a YoY basis, Change in Account Payables climbed as much as 5463.51% in 2023 and fell as far as 994.7% in 2023.
- Year by year, Change in Account Payables stood at -$74000.0 in 2022, then jumped by 5463.51% to $4.0 million in 2023, then grew by 10.73% to $4.4 million in 2024, then sank by 60.18% to $1.8 million in 2025, then soared by 56.63% to $2.7 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $2.7 million in Q1 2026, $1.8 million in Q4 2025, and $918000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | - |
| 10 | Disc Medicine | 2.88 Bn | 2.88 Bn | - | 2.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.74 Mn |
| Mar 31, 2026 | 2.74 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Dec 31, 2025 | 1.75 Mn |
| Sep 30, 2025 | 918,000.00 |
| Sep 30, 2025 | 918,000.00 |
| Jun 30, 2025 | -321,000.00 |
| Jun 30, 2025 | -321,000.00 |
| Mar 31, 2025 | -1.28 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Dec 31, 2024 | 4.40 Mn |
| Sep 30, 2024 | -1.05 Mn |
| Sep 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | -669,000.00 |
| Jun 30, 2024 | -669,000.00 |
| Mar 31, 2024 | -7.36 Mn |
| Mar 31, 2024 | -7.36 Mn |
| Dec 31, 2023 | 3.97 Mn |
| Dec 31, 2023 | 3.97 Mn |